Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on.

The ESMO 2024 Annual Congress heard from the randomized Phase II ImmunoCobiVem trial that a switch to immunotherapy after only 3 months treatment with drugs targeted to the mutation gave equivalent or better survival than continuing with targeted therapy.